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Factors Associated With Intracerebral Hemorrhage After
Thrombolytic Therapy for Ischemic Stroke
Pooled Analysis of Placebo Data From the Stroke-Acute Ischemic NXY
Treatment (SAINT) I and SAINT II Trials
Brett Cucchiara, MD; Scott E. Kasner, MD; David Tanne, MD; Steven R. Levine, MD;
Andrew Demchuk, MD; Steven R. Messe, MD; Lauren Sansing, MD; Kennedy R. Lees, MD;
Patrick Lyden, MD; for the SAINT Investigators
Background and Purpose—A number of factors have been associated with postthrombolysis intracerebral hemorrhage, but
these have varied across studies.
Methods—We examined patients with acute ischemic stroke treated with intravenous tissue plasminogen activator within
3 hours of symptom onset who were enrolled in the placebo arms of 2 trials (Stroke-Acute Ischemic NXY Treatment
[SAINT] I and II Trials) of a putative neuroprotectant. Early CT changes were graded using the Alberta Stroke Program
Early CT Score (ASPECTS). Post–tissue plasminogen activator symptomatic intracerebral hemorrhage was defined as
a worsening in National Institutes of Health Stroke Scale of 4 points within 36 hours with evidence of hemorrhage
on follow-up neuroimaging. Good clinical outcome was defined as a modified Rankin scale of 0 to 2 at 90 days.
Results—Symptomatic intracerebral hemorrhage occurred in 5.6% of 965 patients treated with tissue plasminogen activator. In
multivariable analysis, symptomatic intracerebral hemorrhage was increased with baseline antiplatelet use (single antiplatelet:
OR, 2.04, 95% CI, 1.07 to 3.87, P0.03; double antiplatelet: OR, 9.29, 3.28 to 26.32, P0.001), higher National Institutes
of Health Stroke Scale score (OR, 1.09 per point, 1.03 to 1.15, P0.002), and CT changes defined by ASPECTS (ASPECTS
8 to 9: OR, 2.26, 0.63 to 8.10, P0.21; ASPECTS 7: OR, 5.63, 1.66 to 19.10, P0.006). Higher National Institutes of
Health Stroke Scale was associated with decreased odds of good clinical outcome (OR, 0.82 per point, 0.79 to 0.85, P0.001).
There was no relationship between baseline antiplatelet use or CT changes and clinical outcome.
Conclusions—Along with higher National Institutes of Health Stroke Scale and extensive early CT changes, baseline
antiplatelet use (particularly double antiplatelet therapy) was associated with an increased risk of post–tissue
plasminogen activator symptomatic intracerebral hemorrhage. Of these factors, only National Institutes of Health Stroke
Scale was associated with clinical outcome. (Stroke. 2009;40:3067-3072.)
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Symptomatic intracerebral hemorrhage (ICH) complicatesthrombolytic therapy for acute ischemic stroke in approx-
imately 6% of patients and is associated with very poor
outcome.1–3 A number of factors have been associated with
an increased risk of postthrombolysis ICH. In a recent
systematic review, the presence of early hypodensity on CT,
elevated serum glucose, and history of diabetes were most
consistently associated with increased risk.4 Increasing stroke
severity, longer time to treatment, higher pretreatment blood
pressure, lower platelet count, history of cardiac disease,
history of congestive heart failure, prior antiplatelet therapy, use
of antiplatelet agents other than aspirin, advanced age, and
nonsmoking status have also been associated with increased risk
in some studies.3–9 We examined factors associated with
postthrombolysis ICH in the placebo arm of 2 large companion
acute stroke neuroprotectant trials (Stroke-Acute Ischemic NXY
Treatment [SAINT] I and SAINT II Trials). We also examined
the impact of these factors on final clinical outcome.
Methods
Detailed descriptions of the SAINT I and SAINT II trials have been
published previously.10,11 These trials enrolled patients from May
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2003 to June 2006 and involved 520 centers in multiple countries
worldwide. Briefly, the trials were companion randomized trials with
similar design and inclusion/exclusion designed to test the efficacy
of the putative neuroprotectant NXY-059 compared with placebo in
acute ischemic stroke. Patients treated with intravenous tissue
plasminogen activator (tPA) within 3 hours of symptom onset
according to local treatment practices were eligible for enrollment in
both SAINT trials. Given the possibility of an interaction between
NXY-059 and postthrombolysis hemorrhage, we included in our
analysis only patients randomized to placebo in the 2 trials. Given
the similar designs of SAINT I and SAINT II, data were pooled. All
study procedures were approved by local Institutional Review
Boards as appropriate.
Patients
Patients were eligible for enrollment in the SAINT trials if they had
a clinical diagnosis of acute ischemic stroke, a National Institutes of
Health Stroke Scale (NIHSS) score 6 of which 2 points had to be
for limb weakness, were 18 years of age, were not in a coma, and
had no history of severe renal disease. Written informed consent was
obtained from patients or legally acceptable surrogates. For this
analysis, only enrolled patients treated with tPA were included.
Procedures
As part of the SAINT protocols, formal clinical assessments with the
NIHSS occurred at baseline and 24 and 72 hours after enrollment and
were done by personnel trained and certified in its performance.
Antiplatelet use was defined as a patient or family report that the
patient took aspirin, ticlopidine, clopidogrel, triflusal, cilostazol, or
dipyridamole within the 3 days immediately before the stroke for
which they were enrolled. Early CT changes were graded using the
Alberta Stroke Program Early CT Score (ASPECTS). ASPECTS is
a semiquantitative grading scheme that assesses hypoattenuation on
CT in 10 brain regions supplied by the middle cerebral artery.12
Scores range from 0 to 10, with 10 being a normal CT and 0
representing extensive, complete middle cerebral artery territory
hypoattenuation. All patients treated with thrombolytic therapy
underwent systematic follow-up neuroimaging at 72 hours after
enrollment. Earlier repeat neuroimaging was mandated if neurolog-
ical deterioration occurred. Post-tPA symptomatic ICH (sICH) was
defined as a worsening in NIHSS score of4 points within 36 hours
with evidence of any hemorrhage on follow-up neuroimaging.
Asymptomatic ICH (asICH) was defined as the presence of any
hemorrhage without neurological worsening. Interpretation of all
neuroimaging studies was performed by a central reader blinded to
treatment. Final clinical outcome was categorized based on modified
Rankin scale (mRS) assessment at 90 day follow-up by trained and
certified personnel.
Statistical Analysis
Initial univariable analysis compared baseline factors between those
with sICH, asICH, and no ICH. Our selection of baseline factors for
testing paralleled the analysis in the Multicenter rt-PA Acute Stroke
Survey, a large observational study of hemorrhage risk after
thrombolytic therapy, with several modifications.3 First, we analyzed
NIHSS and onset to treatment time as continuous variables given that
these data were available in our data set, whereas in the Multicenter
Stroke Survey, these were collected and therefore analyzed only as
categorical variables. Second, we divided antiplatelet therapy into
use of single versus double antiplatelet agents as opposed to aspirin
versus “other antiplatelets” because this seemed biologically to be
more sensible in terms of potential hemorrhage risk. Third, we used
ASPECTS grading to assess CT hypodensity as opposed to the local
assessment of more than one third versus less than one third middle
cerebral artery territory involvement. This reflects the fact that
assessment of early hypodensity was only performed systematically
with ASPECTS in our data set and is supported by the greater
interrater reliability of ASPECTS.12 Fourth, we additionally tested
the specific factors ischemic heart disease and congestive heart
failure in lieu of “other cardiac disease,” the category used in the
Multicenter Stroke Survey. We felt this was appropriate because of
the increased precision of these factors and because data from
European Cooperative Acute Stroke Study (ECASS II) suggested
that congestive heart failure was an independent predictor of sICH.7
Multivariable analysis was performed using logistic regression,
including variables significant at P0.10, in the univariable analysis.
We used similar methods to test the role of these factors on clinical
outcome with good outcome defined as a mRS of 0 to 2 at 3 months
poststroke.
Results
A total of 965 subjects were treated with intravenous tPA and
enrolled in the SAINT trials. The mean age was 6813 years,
57% of subjects were male, and 92% were white. The mean
time from symptom onset to treatment with tPA was 14533
minutes. The median and mean NIHSS at enrollment was 14.
sICH occurred in 5.6% (95% CI, 4.1% to 7.0%) and asICH in
17.3% (95% CI, 14.9% to 19.7%). Follow-up neuroimaging
was performed with CT in 91% of patients and MRI in 9%.
There was no difference in the rate of sICH or asICH based
on the type of follow-up neuroimaging. Characteristics of
enrolled patients by ICH status are shown in Table 1. For
purposes of comparison with prior studies, absolute hemor-
rhage rates associated with various factors are presented in
the Figure.
Multivariable analysis showed that risk of sICH was in-
creased with antiplatelet use at the time of enrollment, particu-
larly with double antiplatelet therapy (single antiplatelet: OR,
2.04, 1.07 to 3.87, P0.03; double antiplatelet: OR, 9.29, 3.28 to
26.32, P0.001), higher NIHSS score (OR, 1.09 per point, 1.03
to 1.15, P0.002), and lower ASPECTS (ASPECTS 8 to 9: OR,
2.26, 0.63 to 8.10, P0.21; ASPECTS 7: OR, 5.63, 1.66 to
19.10, P0.006) (Table 2). There was an inverse relationship
between risk of sICH and history of stroke (OR, 0.13, 0.03 to
0.60, P0.009).
Risk of asICH was increased with older age (OR, 1.03
per year, 1.02 to 1.05, P0.001), higher NIHSS (OR, 1.07
per point, 1.03 to 1.10, P0.001), and lower ASPECTS
(ASPECTS 8 to 9: OR, 1.05, 0.42 to 2.64, P0.92;
ASPECTS 7: OR, 4.43, 1.72 to 11.38, P0.002) (Table 3).
Risk of asICH was lower with antiplatelet use (single antiplate-
let: OR, 0.59, 0.38 to 0.93, P0.02; double antiplatelet: OR,
0.76, 0.28 to 2.07, P0.59).
Risk of any ICH was increased with greater age (OR, 1.03 per
year, 1.02 to 1.05, P0.001), higher NIHSS (OR, 1.07 per point,
1.04 to 1.11, P0.001), and lower ASPECTS (ASPECTS 8 to 9:
OR, 1.36, 0.62 to 3.01, P0.45; ASPECTS 7: OR, 4.82, 2.0
to 11.5, P0.001) (Table 4).
To further characterize the relationship between double
antiplatelet therapy and risk of sICH, we analyzed the specific
antiplatelet regimen for the 43 patients found to be on double
antiplatelet therapy. This included 34 patients on aspirin plus
clopidogrel, 5 on aspirin plus dipyridamole, 2 on aspirin plus
ticlopidine, and one each on aspirin plus triflusal and aspirin
plus cilostazol. All sICH in the double antiplatelet group
occurred in patients on combination aspirin and clopidogrel.
An additional exploratory analysis assessing the relation-
ship between serum glucose measured at 24 hours after
enrollment and risk of sICH was performed. This was done in
response to observations from the ECASS II trial, which
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showed an increased risk of ICH with elevated 24-hour, but
not baseline, glucose.13 Glucose measurements at 24 hours
were available for 864 of the patients. In contrast to baseline
glucose, which was not associated with sICH, there was a
significant association between 24-hour glucose and sICH in
univariable analysis (OR, 1.07 per 10 mg/dL, 1.03 to 1.11,
P0.002); this relationship persisted in multivariable analy-
sis (OR, 1.07 per 10 mg/dL, 1.02 to 1.12, P0.007). There
was no significant difference in this association between
patients with and without a history of diabetes.
Factors Associated With Clinical Outcome
Overall, 46% of patients treated with tPA had a good outcome
(defined as mRS 0 to 2) and 14% of patients died. Only 6%
of those with sICH had a good outcome, and 61% died.
In multivariable analysis, a good outcome was less likely in
older patients (OR, 0.96 per year, 0.95 to 0.98, P0.001),
those with a history of congestive heart failure (OR, 0.47,
0.25 to 0.87, P0.02), those with higher systolic blood
pressure (OR, 0.91 per 10 mm Hg, 0.84 to 0.99, P0.03), and
higher NIHSS (OR, 0.82, 0.79 to 0.85, P0.001) (Table 5).
Good outcome was more likely with higher diastolic blood
pressure (OR, 1.13 per 10 mm Hg, 1.00 to 1.27, P0.05).
Notably, there was no relationship between antiplatelet use
and outcome (single antiplatelet: OR, 0.98, 0.68 to 1.43,
P0.93; double antiplatelet: OR, 0.74, 0.32 to 1.73, P0.49).
Discussion
In this analysis of a prospective cohort of carefully monitored
patients treated with intravenous tPA, we found an increased
risk of sICH associated with greater stroke severity, as
measured by the NIHSS, and major, extensive early infarct
changes on CT scan, as defined by ASPECTS 7. We also
found a significant relationship between baseline antiplatelet
use, particularly involving double antiplatelet therapy, and
risk of sICH. Interestingly, there was no increased risk of
overall ICH associated with antiplatelet use, largely because
the risk of asICH was actually lower in the antiplatelet group.
One possible explanation for these findings is that antiplatelet
use does not increase the risk of hemorrhage itself, but if
hemorrhage occurs, it is more likely to become clinically
significant, presumably due to continued bleeding related to
the antiplatelet-induced coagulopathy. To our knowledge, the
finding of a particularly increased risk of postthrombolysis
sICH associated with prior double antiplatelet therapy has not
been previously described, although it is perhaps not surpris-
Table 1. Characteristics of Enrolled Patients by ICH Status
Variable N
sICH
(n54)
asICH
(n167)
No ICH
(n744)
sICH OR
(95% CI)
asICH OR
(95% CI)
Age, years 965 72.912.3 71.011.8 67.013.3 1.04/year (1.01–1.07) 1.03/year (1.01–1.04)
Male sex 965 56% 59% 56% 0.96 (0.55–1.68) 1.10 (0.78–1.54)
Hypertension 965 70% 74% 71% 0.95 (0.52–1.74) 1.12 (0.77–1.64)
Diabetes 965 19% 25% 19% 1.00 (0.49–2.03) 1.43 (0.96–2.13)
Smoking 963 9% 22% 23% 0.36 (0.14–0.91) 0.97 (0.65–1.46)
Prior stroke 965 4% 12% 14% 0.23 (0.05–0.95) 0.81 (0.49–1.35)
Atrial fibrillation 965 37% 29% 27% 1.57 (0.88–2.79) 1.11 (0.76–1.60)
Ischemic heart disease 965 31% 30% 28% 1.15 (0.63–2.09) 1.07 (0.74–1.55)
Congestive heart failure 965 15% 10% 9% 1.70 (0.77–3.75) 1.04 (0.59–1.84)
Antiplatelet use 965
None 628 43% 73% 65% 1.0 (reference) 1.0 (reference)
Single 294 44% 24% 31% 2.19 (1.21–3.97) 0.69 (0.47–1.02)
Double 43 13% 3% 4% 4.74 (1.89–11.9) 0.64 (0.24–1.68)
OTT time 431 14124 14331 14534 0.97/10 minutes (0.85–1.09) 0.98/10 minutes (0.91–1.06)
BP (mm Hg)
SBP 952 15822 15326 15325 1.09/10 (0.97–1.21) 1.00/10 (0.93–1.07)
DBP 952 7916 8017 8227 0.90/10 (0.76–1.06) 0.95/10 (0.86–1.05)
MAP 953 10515 10417 10517 1.00/10 (0.84–1.18) 0.97/10 (0.87–1.07)
NIHSS score* 965 17 (12, 19) 16 (12, 19) 13 (9, 17) 1.10/point (1.05–1.15) 1.08/point (1.05–1.11)
CT ASPECTS 952
10 881 87% 89% 94% 1.0 (reference) 1.0 (reference)
8–9 45 6% 6% 4% 1.40 (0.41–4.8) 1.46 (0.70–3.04)
7 26 8% 5% 2% 4.6 (1.44–14.7) 3.24 (1.36–7.72)
Glucose, mg/dL 836 13553 14054 13148 1.02/10 mg/dL (0.96–1.08) 1.03/10 mg/dL (1.00–1.07)
Platelet count,
1000/mm3 684 21556 21861 23370
0.96/10/dl1000/mm3
(0.91–1.01)
0.97/101000/mm3
(0.94–1.00)
*NIHSS expressed as medians and intraquartile ranges; all other continuous variables expressed as means and SDs.
N indicates no. of patients with available data for each variable; OTT, onset to treatment; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood
pressure; MAP, mean arterial pressure.
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ing given evidence of increased bleeding complications with
double antiplatelet therapy in stroke prevention trials.14 This
observation should be considered preliminary, however,
given the small number of patients in our cohort on double
antiplatelet therapy.
Several previous studies have suggested an increased risk
of sICH in patients on antiplatelet therapy, although this has
not been shown to influence overall clinical outcome in
patients treated with thrombolytic therapy.5,7–9 In tPA-treated
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Figure. Risk of intracerebral hemorrhage by (A) age; (B) NIHSS score; (C) early CT changes defined by ASPECT score; (D) prior anti-
platelet use; (E) baseline serum glucose; and (F) baseline platelet count.
Table 2. Multivariable Logistic Regression Model for sICH
Versus No ICH
Factor OR (95% CI) P
Age per year 1.02 (0.99–1.05) 0.17
Smoking 0.49 (0.18–1.36) 0.17
Prior stroke 0.13 (0.03–0.60) 0.009
Antiplatelet therapy
Single 2.04 (1.07–3.87) 0.03
Double 9.29 (3.28–26.32) 0.001
NIHSS per point 1.09 (1.03–1.15) 0.002
ASPECTS
8–9 2.26 (0.63–8.10) 0.21
7 5.63 (1.66–19.10) 0.006
Note. Analysis incorporated all factors significant in univariable analysis at
P0.10. N784.
Table 3. Multivariable Logistic Regression Model for asICH
Versus No ICH
Factor OR (95% CI) P
Age per year 1.03 (1.02–1.05) 0.001
Antiplatelet therapy
Single 0.59 (0.38–0.93) 0.02
Double 0.76 (0.28–2.07) 0.59
NIHSS, per point 1.07 (1.03–1.10) 0.001
ASPECTS
8–9 1.05 (0.42–2.64) 0.92
7 4.43 (1.72–11.38) 0.002
Glucose per 10 mg/dL 1.03 (1.0–1.07) 0.07
Note. Analysis incorporated all factors significant in univariable analysis at
P0.10 except for platelet count, which was missing for a substantial no. of
subjects. Analysis, including platelet count in the multivariable model, did not
substantially alter any of the results. N784.
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patients in ECASS II, sICH occurred in 18.9% of patients on
aspirin compared with 6.2% of those not on aspirin. Our
results indicate a less substantial differential risk with sICH
occurring in 8.2% of patients on a single antiplatelet agent
compared with 3.7% on no antiplatelet agent. In our study,
final clinical outcome was not modified by antiplatelet use
despite the increased risk of sICH. This raises the possibility
that the increased risk of bleeding with antiplatelet medica-
tions in some patients is balanced by beneficial effects in
other patients, perhaps mediated by increased reperfusion or
a decreased risk of vessel reocclusion. In the National
Institute of Neurological Diseases (NINDS) and Stroke tPA
trial, patients with prior aspirin use had a lower rate of early
clinical deterioration, although the mechanism underlying
this finding was unclear.15 On the other hand, animal models
examining the interaction between antiplatelet agents and tPA
have shown complex and contradictory results with aspirin
counterintuitively attenuating thrombolysis and reducing hem-
orrhage in some models and increasing hemorrhage without
substantially altering thrombolytic efficacy in others.16–18
In our cohort, we did not find a relationship between either
baseline serum glucose or history of diabetes and risk of
sICH. Several other large clinical trials of intravenous
thrombolysis, including ECASS II, Alteplase ThromboLysis
for Acute Noninterventional Therapy in Ischemic Stroke
(ATLANTIS), and an initial analysis of the NINDS trial, also
failed to find an independent association between baseline
glucose and sICH, although a subsequent reanalysis of
NINDS incorporating the placebo-treated patients and using a
different statistical approach did report an increased risk of
sICH with hyperglycemia.6,7,19 In contrast, large observa-
tional studies in clinical practice such as the Multicenter tPA
Stroke Survey Group, Canadian Alteplase Stroke Effective-
ness Study, and Safe Implementation of Thrombolysis in
Stroke-MOnitoring STudy (SITS-MOST) have consistently
demonstrated an association between sICH and
hyperglycemia.2,3,8
In the ECASS II trial, the relationship between hypergly-
cemia and parenchymal ICH varied significantly based on the
timing of glucose measurement.13 For subjects with elevated
baseline glucose but normal 24-hour glucose, there was no
increased risk of parenchymal hemorrhage. In contrast, non-
diabetic subjects with hyperglycemia at 24-hour measure-
ment (with or without baseline hyperglycemia) had a very
substantial increased risk of parenchymal hemorrhage. The
findings of our analysis largely confirm these observations
from the ECASS II study. Therefore, it appears that timing of
glucose measurement may be critical to its association with
sICH. This also raises the important question of the cause-
and-effect relationship between hyperglycemia and sICH.
Given that most sICH after thrombolysis occurs within the
first 24 hours,6 and that hyperglycemia may represent a
reactive “stress response” to critical illness, it is plausible that
hyperglycemia at the 24-hour time point is actually precipi-
tated by sICH as opposed to being predictive of it, thus
accounting for the observed association.
In this respect, the discrepancy between data from clinical
trials and from observational studies in clinical practice is
intriguing. It could be speculated that glucose measurements
recorded in clinical trials might occur more reliably pre-
enrollment and therefore truly at baseline, whereas those
collected in observational studies in clinical practice might
often reflect measurements at somewhat later time points,
introducing a potential important bias confounding the per-
ceived relationship between hyperglycemia and sICH. The
role of hyperglycemia in promoting sICH after thrombolytic
therapy remains to be clarified, and future studies should
closely examine the relationship between sICH and glucose
levels at baseline and later time points.
An inverse relationship between the risk of sICH and
history of stroke was identified in our study, a finding that
was unexpected and has not been found in previous studies.
Patients with pre-existing significant disability, defined as a
mRS of 2, were excluded from enrollment in the SAINT
trials and thus not represented in our cohort. It is possible that
Table 4. Multivariable Logistic Regression Model for any ICH
Versus No ICH
Factor OR (95% CI) P
Age per year 1.03 (1.02–1.05) 0.001
Antiplatelet therapy
Single 0.77 (0.52–1.14) 0.19
Double 1.56 (0.75–3.27) 0.24
NIHSS, per point 1.07 (1.04–1.11) 0.001
ASPECTS
8–9 1.36 (0.62–3.01) 0.45
7 4.82 (2.02–11.52) 0.001
Glucose per 10 mg/dL 1.03 (1.0–1.06) 0.07
Note. Analysis incorporated all factors significant in univariable analysis at
P0.10 except for platelet count, which was missing for a substantial no. of
subjects. Analysis including platelet count in the multivariable model did not
substantially alter any of the results. N827.
Table 5. Multivariable Logistic Regression Model for Good
Outcome
Factor OR (95% CI) P
Age per year 0.96 (0.95–0.98) 0.001
Male sex 1.18 (0.84–1.66) 0.34
Hypertension 0.95 (0.65–1.40) 0.80
Smoking 0.85 (0.56–1.29) 0.43
Atrial fibrillation 0.93 (0.62–1.38) 0.70
Prior coronary heart failure 0.47 (0.25–0.87) 0.02
Antiplatelet therapy
Single 0.98 (0.68–1.43) 0.93
Double 0.74 (0.32–1.73) 0.49
Systolic blood pressure per 10 mm Hg 0.91 (0.84–0.99) 0.03
Diastolic blood pressure per 10 mm Hg 1.13 (1.00–1.27) 0.05
NIHSS, per point 0.82 (0.79–0.85) 0.001
ASPECTS
8–9 0.83 (0.38–1.77) 0.62
7 0.49 (0.18–1.35) 0.17
Glucose per 10 mg/dL 0.97 (0.94–1.00) 0.07
Note. Analysis included factors significantly associated with good outcome in
univariable analysis at P0.10. Good outcome defined as mRS 0 to 2. N798.
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the exclusion of patients with prior stroke associated with
major disability could account for the discrepant risk of sICH
seen in our cohort. Alternatively, and probably most likely,
this observation is spurious.
A final important observation in our study relates to the
risk of postthrombolysis hemorrhage associated with increas-
ing age. Marketing authorization for recombinant tPA does
not extend to patients aged 80 years in Europe, and
concerns about safety in this population are frequently ex-
pressed. Although we found an association between age and
asICH, there was no association between age and sICH in
multivariate analysis in our cohort. Given that almost 20% of
our total patient population was aged 80 years old, this
provides important reassuring safety data supporting
thrombolytic therapy in this demographic group. These find-
ings are in agreement with other reports that have assessed the
risk of sICH after thrombolysis in the elderly.20,21
Our study has a number of strengths, including prospective
data collection using a standardized case report form across
study sites, central analysis of all imaging studies, and use of
trained and certified personnel to determine NIHSS and mRS
scores. However, there are also limitations based on the
analysis being post hoc and focused mainly on factors
previously suggested to be related to post-tPA hemorrhage.
Confounding by alternative unmeasured factors associated
with post-tPA hemorrhage is certainly possible. Furthermore,
because data were collected in the setting of a clinical trial,
the enrolled population was highly selected and may not be
representative of the stroke population in clinical practice,
limiting generalizability. In particular, patients with prior
disabling stroke, severe renal disease, or multiple comorbidi-
ties limiting life expectancy were excluded.
In conclusion, we found that patients with higher NIHSS
scores, baseline antiplatelet use (particularly double antiplate-
let therapy), and major, extensive early CT findings were at
increased risk of sICH after intravenous tPA. The finding of
a particularly increased risk of sICH with double antiplatelet
therapy is novel and requires further confirmation in future
studies. Of these factors, only NIHSS score was associated
with final clinical outcome.
Given the lack of an association between prior use of
antiplatelet therapy and clinical outcome, our data do not
support using this factor to withhold thrombolytic treatment.
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